Telix Pharmaceuticals provided 4QFY22 activities report and cash flow statement

Telix Pharmaceuticals Limited (ASX: TLX) provided a quarterly cash flow statement and associated activities report for the quarter ended 31 December 2022:

• During 4QFY22, the company reported an improvement in its net operating cash flow by AU$6.9 million over the previous quarter to an AU$1.6 million inflow for the quarter.
• Its cash receipts from customers were AU$72.2 million, which increased by 62% from AU$44.5 million in the previous quarter.
• The company has reported its 4QFY22 revenue of AU$78.2 million from global sales of Illuccix compared to AU$55.3 million in the previous quarter, registering a growth of approx. 41%.
• Operating and selling, general, and administration costs were lower by AU$4.7 million compared to the previous quarter, indicating enhanced working capital management.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com